Drug Trial Radar · NCT05393063
A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 2022
Primary completion
Jun 2023
Study completion Jun 2024
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to characterize the safety, tolerability and anti-tumor activity of AK127 as a single agent in adult subjects with advanced solid tumor malignancies.
Conditions
- Advanced Solid Tumors
Interventions
AK127Drug
Subjects will receive AK127 by intravenous administration(administered on Day 1 of each cycle, Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first
- Number of participants with a Dose Limiting Toxicity (DLT)Time frame: During the first 21 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.